ARS Wealth Advisors Group LLC Purchases 124 Shares of Eli Lilly and Company (NYSE:LLY)

ARS Wealth Advisors Group LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 6.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,041 shares of the company’s stock after purchasing an additional 124 shares during the quarter. ARS Wealth Advisors Group LLC’s holdings in Eli Lilly and Company were worth $1,190,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Provence Wealth Management Group lifted its position in shares of Eli Lilly and Company by 17.4% in the fourth quarter. Provence Wealth Management Group now owns 2,801 shares of the company’s stock valued at $1,633,000 after buying an additional 415 shares during the last quarter. Blue Fin Capital Inc. raised its position in shares of Eli Lilly and Company by 3.2% in the fourth quarter. Blue Fin Capital Inc. now owns 10,215 shares of the company’s stock valued at $5,955,000 after buying an additional 314 shares in the last quarter. VeraBank N.A. grew its holdings in shares of Eli Lilly and Company by 2.1% during the 4th quarter. VeraBank N.A. now owns 3,825 shares of the company’s stock worth $2,230,000 after purchasing an additional 78 shares in the last quarter. Legacy Financial Advisors Inc. raised its position in shares of Eli Lilly and Company by 5.8% in the 4th quarter. Legacy Financial Advisors Inc. now owns 2,807 shares of the company’s stock valued at $1,637,000 after buying an additional 154 shares in the last quarter. Finally, Knuff & Co LLC boosted its holdings in shares of Eli Lilly and Company by 7.0% in the 4th quarter. Knuff & Co LLC now owns 767 shares of the company’s stock valued at $447,000 after purchasing an additional 50 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. BMO Capital Markets raised their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday. Truist Financial increased their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Finally, Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $20.94 during trading on Friday, reaching $734.97. 4,595,138 shares of the stock traded hands, compared to its average volume of 2,629,045. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The business has a fifty day simple moving average of $761.06 and a two-hundred day simple moving average of $671.38. The company has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the company earned $1.62 earnings per share. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.